APA

Herman S. E. M., Montraveta A., Niemann C. U., Mora-Jensen H., Gulrajani M., Krantz F., Mantel R., Smith L. L., McClanahan F., Harrington B. K., Colomer D., Covey T., Byrd J. C., Izumi R., Kaptein A., Ulrich R., Johnson A. J., Lannutti B. J., Wiestner A. & Woyach J. A. (20180316). The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Herman Sarah E M, Montraveta Arnau, Niemann Carsten U, Mora-Jensen Helena, Gulrajani Michael, Krantz Fanny, Mantel Rose, Smith Lisa L, McClanahan Fabienne, Harrington Bonnie K, Colomer Dolors, Covey Todd, Byrd John C, Izumi Raquel, Kaptein Allard, Ulrich Roger, Johnson Amy J, Lannutti Brian J, Wiestner Adrian and Woyach Jennifer A. 20180316. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Herman S. E. M., Montraveta A., Niemann C. U., Mora-Jensen H., Gulrajani M., Krantz F., Mantel R., Smith L. L., McClanahan F., Harrington B. K., Colomer D., Covey T., Byrd J. C., Izumi R., Kaptein A., Ulrich R., Johnson A. J., Lannutti B. J., Wiestner A. and Woyach J. A. (20180316). The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Herman Sarah E M, Montraveta Arnau, Niemann Carsten U, Mora-Jensen Helena, Gulrajani Michael, Krantz Fanny, Mantel Rose, Smith Lisa L, McClanahan Fabienne, Harrington Bonnie K, Colomer Dolors, Covey Todd, Byrd John C, Izumi Raquel, Kaptein Allard, Ulrich Roger, Johnson Amy J, Lannutti Brian J, Wiestner Adrian and Woyach Jennifer A. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20180316.